Type 2 diabetes is a complex chronic disease that occurs when the body cannot make enough insulin and/or use it effectively. People living with type 2 diabetes require ongoing, frequent medication to keep their blood sugar levels under control, and to reduce the risk of long-term complications.
Symptoms of uncontrolled diabetes may include excessive urination, extreme thirst, tiredness and fatigue, yeast infections, blurred vision, and weight loss. Over time, patients can develop even more serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems.
Adherence to medication is low among many patients with this condition
The American Diabetes Association (ADA) encourages treatment options that address adherence by reducing the complexity of treatment regimens, the frequency of administration, and the reliance on human behavior for appropriate dosing
The GLP-1 (Glucagon-like peptide) hormone is naturally produced in the gut and gets released in response to food. When released, GLP-1 stimulates insulin production in the pancreas, lowering the amount of glucose in the blood.
GLP-1 receptor agonists are a class of drugs that mimic the action of the GLP-1 hormone and are also associated with weight loss. Multiple products in this class are currently approved for the treatment of type 2 diabetes and/or obesity and are generally considered safe and effective.
Many of the currently approved GLP-1 treatments are taken by a self-administered injection. Even with the availability of an oral GLP-1 on the market, medication adherence continues to be a challenge for many patients
Our lead products, NPM-119 and NPM-115, are GLP-1 receptor agonists under development for the treatment of patients with type 2 diabetes and obesity, respectively. As a result of our revolutionary NanoPortal implant technology, they can be easily inserted underneath the skin during quick, outpatient procedures by a healthcare professional and are designed to steadily release exenatide for up to 6 months with a single implant.
We believe guaranteed adherence with NPM-119 and NPM-115 have the potential to improve patient outcomes in the real-world setting.
Alternative treatment option with minimal reliance on patient behavior
Caretakers, physicians and family members are assured patients are receiving their medicine as prescribed
Subdermal insertion/removal procedures every 6 months that correspond with bi-annual office visits